Form 4: Adaptive Biotechnologies Director Acquires Shares and Options

Director Peter M Neupert reports acquisition of Adaptive Biotechnologies stock and options in a Form 4 filing.

Summary

• On March 4, 2025, Peter M Neupert, a director of Adaptive Biotechnologies Corp, acquired 15,394 shares of common stock.
• The acquisition price was $0.
• Following the transaction, Neupert directly owns 184,690 shares of common stock.
• Neupert also acquired 23,726 stock options with an exercise price of $8.12, exercisable from March 4, 2025, to March 4, 2035.
• The options vest in equal monthly installments over one year from March 4, 2025, contingent upon continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be seen as a positive sign, but it's not overwhelmingly so.

Positives

• The director's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the options is contingent upon continued service as a director, suggesting an ongoing commitment to the company.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing indicates the director's continued investment in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates